methylprednisolone + recombinant human granulocyte colony-stimulating factor

This is a combination therapy consisting of methylprednisolone, a synthetic glucocorticoid corticosteroid, and recombinant human granulocyte colony-stimulating factor (rhG-CSF), a biologic cytokine. Methylprednisolone acts primarily as an anti-inflammatory and immunosuppressive agent by binding to the glucocorticoid receptor and modulating gene expression to suppress immune responses. Recombinant human G-CSF stimulates the proliferation, differentiation, and activation of neutrophil precursors in the bone marrow by binding to the G-CSF receptor on hematopoietic cells. The combination has been studied for synergistic effects in promoting functional recovery after spinal cord injury, improving steroid responsiveness in severe alcoholic hepatitis, enhancing hematopoietic recovery after chemotherapy-induced neutropenia, and inducing differentiation/apoptosis of leukemic cells. The two agents are typically administered together for their complementary mechanisms—methylprednisolone reduces inflammation while rhG-CSF promotes myeloid cell regeneration.